

OFFICIAL

1/24/02

001

#19/ENE

Attorney's Docket No.: 10223-006001

ES/1/24/02

OFFICIAL COMMUNICATION

FACSIMILE

FOR THE PERSONAL ATTENTION OF:

EXAMINER MARGARET E. JAMROZ

GROUP 1644 FAX NO: 1-703-746-7360

Number of pages including this page 12

Applicant : Lars Hellman
Serial No. : 09/401,636
Filed : September 22, 1999
Title : IMMUNOGENIC POLYPEPTIDES FOR INDUCING ANTI-SELF IgE RESPONSES


Art Unit : 1644
Examiner : Margaret E. Jamroz
FACSIMILE COMMUNICATION

Commissioner for Patents
Washington, D.C. 20231

Sir:

Attached to this facsimile communication cover sheet is a Response to Final Office Action mailed December 4, 2001, faxed this day of January 23, 2002, to Group 1644, the United States Patent and Trademark Office.

Respectfully submitted,


J. Patrick Finn III, Ph.D.
Reg. No. 44,109

Date: January 23, 2002

Fish & Richardson P.C., P.A.
60 South Sixth Street, Suite 3300
Minneapolis, MN 55402
Telephone: (612) 335-5070
Fax: (612) 288-9696

60070129.doc

NOTE: This facsimile is intended for the addressee only and may contain privileged or confidential information. If you have received this facsimile in error, please immediately call us collect at (612) 335-5070 to arrange for its return. Thank you.

Received from < 612 288 9696 > at 1/23/02 5:25:50 PM [Eastern Standard Time]

Attorney's Docket No.: 10223-006001

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Lars Hellman
Serial No. : 09/401,636
Filed : September 22, 1999
Title : IMMUNOGENIC POLYPEPTIDES FOR INDUCING ANTI-SELF IgE
RESPONSES

Art Unit : 1644
Examiner : Margaret E. Jamroz

BOX AF
Commissioner for Patents
Washington, D.C. 20231

RESPONSE

In response to the action mailed December 4, 2001, please amend the application as follows:

In the specification:

Please amend the title to read as follows:

-- IMMUNOGENIC POLYPEPTIDES FOR INDUCING ANTI-SELF IgE
RESPONSES --

In the claims:

Please amend claims 1, 6, 7, 25, 27, 30-33, 35, 38-41, 45-48, 50, and 52-54 as follows:

--1. (Amended Four Times) An immunogenic polypeptide, comprising a self IgE portion and a non-self IgE portion, wherein said immunogenic polypeptide is effective to induce an anti-self IgE response in a mammal, wherein said self IgE portion comprises a CH3 domain of IgE, wherein said non-self IgE portion comprises a CH2 domain of IgE and a CH4 domain of IgE, and wherein said immunogenic polypeptide lacks a CH1 domain of IgE:

CERTIFICATE OF TRANSMISSION BY FACSIMILE

I hereby certify that this correspondence is being transmitted by facsimile to the Patent and Trademark Office on the date indicated below.

Date of Transmission January 23, 2002

Signature Judy Wasilkus

Typed or Printed Name of Person Signing Certificate Judy Wasilkus